Fig. 4From: A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationProportion of IFNAR1-positive cells in tumor samples, in the immunohistochemical analysisBack to article page